From innovation to meaningful technology

Translating innovation into clinically meaningful technology, our CRM systems are imagined, designed and built to improve health and save lives.

Across the globe, MicroPort® CRM strives to ensure the highest levels of performance and quality throughout the entire product life cycle, and to provide timely and reliable information on device performance to physicians and patients.

This Second Edition of 2023 of our Product Performance Report embodies our commitment to update the product performance information regularly and communicate it to physicians and patients. This latest edition includes performance data collected through June 30, 2023 and incorporates the latest information about the company’s most recent leads and pulse generators (pacemakers, ICDs (Implantable Cardioverter Defibrillators), CRT devices (Cardiac Resynchronization Therapy), as well as the most recent updates about product advisories.

As a company, we believe that every patient is important and should be treated equally, and we aim for full transparency with our physicians and patients. Because our products are globally marketed, with the majority of patients outside the United States, MicroPort® CRM provides worldwide data in its Product Performance Report to ensure that patients, physicians and regulators are better and sooner informed.

We continually seek your input to help us enhance our product performance, and we encourage you to provide your comments and suggestions to your local representative. We also urge you to inform your local representative immediately about any indication of potential problem with our devices. Your contributions play a key role in communicating accurate and vital product performance information.